Bormioli Pharma issues a binding offer to acquire GCL Pharma SRL

19.03.2020

Parma (Italy), 19 March 2020- Bormioli Pharma, a Triton Fund IV company, announced it has issued a binding offer for the acquisition of 100% of GCL Pharma, an Italian company of the Guala Closures Group, specialized in the production of plastic, rubber and aluminum closures for pharmaceutical applications.

In 2019 GCL Pharma had a turnover of around 8 million euros. Over the years the company has shown a strong capacity for innovation by continuously improving its product range to meet the strictest pharmaceutical standards. The company's headquarters and production plant are located in Vasto (Chieti).

Bormioli Pharma, a leading company in the production of primary packaging in glass and plastic for pharmaceutical use, continues to invest to become an increasingly strong player in the sector.

This further acquisition, which follows that of Remy & Geiser completed last autumn, allows the company to expand its product range by consolidating its ability to support even the most demanding pharma players.

The transaction is expected to close in the coming weeks.

About Bormioli

Bormioli Pharma operates in close partnership with the pharmaceutical industry and with all the businesses that are engineering the future of healthcare. As a world-renowned player in the packaging industry, Bormioli Pharma serves the pharmaceutical and biopharmaceutical market with integrated glass and plastic containers, closures, and packaging accessories using state-of-the-art materials and technologies.

Each product is a unique combination of rigorous studies, cutting-edge technology, extreme testing, advanced industrial processes, and the finest materials.

As a partner to the pharmaceutical industry, Bormioli Pharma invests and innovates with one goal in mind: improving people’s lives. Bormioli Pharma employees over 1200 people, produces 6.5 billion pieces every year and had an annual turnover of approximately €250 million in 2019.

For more information: www.bormiolipharma.com/en/#

About Guala Closures Group

The Guala Closures Group has over 4,700 employees and operates on 5 continents through 30 production plants and a marketing of its products in over 100 countries. Today the Group sells nearly 20 billion closings yearly with a 2019 turnover of Euro 607 million. Thanks to a policy of continuous business development and technological innovation, the Group is recognized as a reference point worldwide in the production of safety closures for alcohol and is a leader in the production of aluminum closures for spirits, wines and drinks.
Since August 2018, Guala Closures SpA has been listed on the STAR segment of Borsa Italiana, entering the FTSE Italia Mid Cap index in September 2019.

For more information: www.gualaclosures.com/

About Triton

Since its establishment in 1997, Triton has sponsored nine funds, focusing on businesses in the industrial, business services, consumer and healthcare sectors. The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe.

Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth.

The 42 companies currently in Triton's portfolio have combined sales of around €17.2 billion and around 81,400 employees.

For further information: www.triton-partners.com

Press Contacts

Triton
Anja Schlenstedt